fda approval semaglutide mash Wegovy Receives Accelerated for Treating Semaglutide #Wegovy receives Saudi FDA

A new study, the STEP trial, examined semaglutides impact on cardiovascular outcomes in overweight people or people with obesity and established cardiovascular disease

Investigators used overlap weighting to balance baseline characteristics, including age, body mass index, glycemic control, cardiovascular risk factors and comorbidities

Using intravenous vitamin B12 shows how different treatments are used around the world

Brand Names The two FDA-approved brands of semaglutide include: Ozempic (primarily approved for type 2 diabetes) Wegovy (approved specifically for chronic weight management) Both are administered as a once-weekly injection